Key takeaways
- 1:6,000-8,000 GCC SMA incidence vs ~1:10,000 globally, elevated by consanguinity · Al-Jasmi F et al., Orphanet J Rare Dis 2016
- 90% / 85% / 75% estimated newborn-screening coverage in Saudi Arabia / UAE / Qatar, vs under 50% in Oman, Bahrain, and Kuwait · Saudi NBS Programme 2022-2023; MOH UAE NBS reporting
- 60-80/yr annual GCC Zolgensma cases, the bottom-up anchor against which top-down incidence-based sizing is validated · NPHC/MOH UAE programme documentation
- 800-1,200 estimated living GCC SMA Type 2/3 adults from the pre-newborn-screening era, ineligible for gene therapy on age/weight criteria · GCC paediatric neurology network SMA registry 2022
GCC SMA sizing turns on which country's newborn-screening coverage a model assumes, not on the regional incidence rate alone.
GCC SMA incidence runs 1:6,000-8,000 live births, well above the roughly 1:10,000 global rate, driven by consanguinity increasing the frequency of homozygous SMN1 deletion. That elevated incidence alone would justify a larger addressable population than a global-rate model predicts, but incidence is not the binding constraint on near-term commercial volume. Newborn-screening coverage is: an estimated 90% of Saudi births, 85% in the UAE, and 75% in Qatar are screened as of the most recent country-level data, while Oman, Bahrain, and Kuwait remain below 50% and are still implementing. A sizing model built on regional incidence alone, without splitting screening coverage by country, will overstate near-term addressable volume in the lower-coverage states and understate the near-term concentration in Saudi Arabia.
Bottom-up validation confirms the same picture. An estimated 60-80 Zolgensma cases occur across GCC annually, combining newborn-screening-identified and symptomatic patients, a figure that functions as the bottom-up anchor against which any top-down incidence-based estimate should be checked. Alongside this sits a distinct, separately-sized population: an estimated 800-1,200 GCC SMA Type 2/3 patients diagnosed before newborn screening existed, now teenagers and adults with established motor disability, ineligible for gene therapy on age and weight criteria and dependent on chronic therapy or untreated. This pre-screening-era cohort does not shrink as screening coverage expands; it is a fixed, aging population that a sizing model has to size separately from the newborn-screening-era flow, since it is unmet-need chronic-therapy volume, not gene-therapy volume.
GCC SMA sizing — incidence-based estimate versus country-level newborn-screening coverage
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Epidemiology-based (incidence-adjusted) | 1:6,000-8,000 GCC incidence vs 1:10,000 global | Al-Jasmi F et al., Orphanet J Rare Dis 2016 |
| Registry-based (NBS coverage by country) | KSA ~90%; UAE ~85%; Qatar ~75%; others <50% | Saudi NBS Programme 2022-2023; MOH UAE NBS reporting |
| Bottom-up case-count anchor | 60-80 Zolgensma cases/yr | NPHC/MOH UAE programme documentation |
| Pre-NBS legacy cohort | 800-1,200 Type 2/3 adults | GCC paediatric neurology network SMA registry 2022 |
Sources: Al-Jasmi F et al., Orphanet J Rare Dis 2016; Saudi NBS Programme 2022-2023; MOH UAE newborn-screening reporting; GCC paediatric neurology network SMA registry 2022; NPHC SMA programme documentation.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How does GCC newborn-screening coverage vary by country, and what does that mean for near-term gene-therapy-eligible birth-cohort sizing in each market? • Country-by-country NBS coverage rate (KSA ~90%, UAE ~85%, Qatar ~75%, others under 50%) • birth-cohort sizing by country • screening-rollout timeline
- How does the 60-80 annual Zolgensma case count validate or challenge a top-down, incidence-based sizing estimate? • Bottom-up Zolgensma case-count anchor • top-down incidence-based estimate • reconciliation methodology between the two
- What is the size and treatment status of the pre-screening-era Type 2/3 legacy cohort, and how does it differ from the newborn-screening-era flow in commercial terms? • 800-1,200-patient legacy cohort sizing • chronic-therapy addressable-volume modelling • why this population is sized separately from NBS-era flow
What's inside
-
1 · The Binding Constraint 2 pp
- Why newborn-screening coverage by country, not regional incidence alone, determines near-term addressable volume
- Pressure-tested against the 60-80/yr Zolgensma case anchor before the rest of the model is built out
-
2 · Epidemiology-Based Sizing 3 pp
- GCC incidence (1:6,000-8,000) adjusted for consanguinity, against the global 1:10,000 rate
- The structurally larger annual birth cohort this implies
-
3 · Registry-Based Sizing — Country-by-Country NBS Coverage 3 pp
- NBS coverage by country (KSA ~90%, UAE ~85%, Qatar ~75%, others under 50%)
- Birth-cohort and screening-eligible population by country
-
4 · Triangulation & the Zolgensma Case-Count Anchor 3 pp
- Reconciling top-down incidence-based sizing against the 60-80/yr bottom-up case count
- The pre-screening-era Type 2/3 legacy cohort as a separately-sized population
-
5 · Sensitivity Analysis 3 pp
- NBS coverage expansion ranked against incidence rate as the binding assumption
- Scenario ranges tied to Oman/Bahrain/Kuwait screening rollout
-
6 · Editable Excel Model —
- The full triangulated model, re-runnable with your own assumptions
-
7 · Client Alignment Questions 2 pp
- The open sizing questions your team must close before the number is used in planning
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom model delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the GCC SMA opportunity across newborn-screening-era and legacy populations. Custom model in 72 hours.
- 1. Submit your requestSpecify your indication, market, and cohort definition.
- 2. Scoping callAXLRx analyst confirms triangulation methods and comparator set before building.
- 3. DeliveryResearch-verified sizing model in 72 hours with optional analyst readout.
How AXLRx builds this model
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx market sizing model triangulates at least two independent methods, epidemiology-based and registry/case-count-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model (dynamic revenue/uptake).
SMA GCC sizing sources: Al-Jasmi F et al. (Orphanet J Rare Dis 2016) for incidence and consanguinity effect, the Saudi National Newborn Screening Programme and MOH UAE newborn-screening reporting for country-level coverage, and the GCC paediatric neurology network SMA registry for legacy-cohort sizing.
- GCC SMA incidence and consanguinity-effect figures verified against Al-Jasmi F et al., Orphanet J Rare Dis 2016
- Country-level newborn-screening coverage rates verified against Saudi NBS Programme 2022-2023 and MOH UAE reporting
- Pre-NBS legacy cohort sizing and the 60-80/yr Zolgensma case-count anchor verified against GCC paediatric neurology network SMA registry 2022 and NPHC/MOH UAE programme documentation
Frequently asked questions
Deliverables What formats are included with every model?
Every commissioned Market Sizing Model includes an editable 5-sheet Excel model (Cover, Model, Research Validation, QC, Sensitivity) and a PDF methodology brief, no PowerPoint deck, since a sizing model is built to be worked in directly, not presented from. An optional 45-minute analyst readout call is included.
Sources How is the patient count verified?
AXLRx triangulates every sizing estimate across at least two independent methods, epidemiology-based and registry/case-count-based; no single-source number ships unverified.
Customisation Can I size a specific GCC country or subpopulation?
Yes. The intake form captures your indication, target GCC market, and cohort definition. A scoping call confirms scope before research starts. Commission via the intake form to start.